p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1442-1446

  Bonfanti, Marina ^a   Taverna, Stefano ^a   Salmona, Mario ^a   D'Incalci, Maurizio ^a   Broggini, Massimo ^a  

^a Molecular Pharmacology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; ANTENNAPEDIA PROTEIN; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; NUCLEAR PROTEIN; PEPTIDE FRAGMENT; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR;

AMINO ACID SEQUENCE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; OVARY TUMOR; PATHOLOGY;

ANTENNAPEDIA HOMEODOMAIN PROTEIN; ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; FLOW CYTOMETRY; HOMEODOMAIN PROTEINS; HUMANS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0030615324     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pines, J. Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res., 66: 181-212, 1995.
2. 1 cyclins. Cell, 73: 1059-1065, 1993.
3. Fotedar, R., Fitzgerald, P., Rousselle, T., Cannella, D., Doree, M., Messier, H., and Fotedar, A. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene, 12: 2155-2164, 1996.
4. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases (see comments). Nature (Lond.), 366: 701-704, 1993.
5. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
6. Zakut, R., and Givol, D. The tumor suppression function of p21Waf is contained in its N-terminal half ("half-WAF"). Oncogene, 11: 393-395, 1995.
7. wAF1. Cancer Res., 55: 4536-4539, 1995.
8. Yang, Z. Y., Perkins, N. D., Ohno, T., Nabel, E. G., and Nabel, G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo (see comments). Nat. Med., 1: 1052-1056, 1995.
9. Luo, Y., Hurwitz, J., and Massague, J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (Lond.), 375: 159-161, 1995.
10. WAF1 and proliferating cell nuclear antigen. Curr. Biol., 5: 275-282, 1995.
11. Chen, J., Jackson, P. K., Kirschner, M. W., and Dutta, A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (Lond.), 374: 386-388, 1995.
12. Chen, I. T., Akamatsu, M., Smith, M. L., Lung, F. D., Duba, D., Roller, P. P., Fornace, A. J., Jr., and O'Connor, P. M. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene, 12: 595-607, 1996.
13. Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., and Dutta, A. Cyclin-binding motifs are essential for the function of p21CIP1. Mol. Cell. Biol., 16: 4673-4682, 1996.
14. Goubin, F., and Ducommun, B. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene, 10: 2281-2287, 1995.
15. Nakanishi, M., Robetorye, R. S., Adami, G. R., Pereira Smith, O. M., and Smith, J. R. Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. EMBO J., 14: 555-563, 1995.
16. Lin, J., Reichner, C., Wu, X., and Levine, A. J. Analysis of wild-type and mutant p21WAF-l gene activities. Mol. Cell. Biol., 16: 1786-1793, 1996.
17. Theodore, L., Derossi, D., Chassaing, G., Llirbat, B., Kubes, M., Jordan, P., Chneiweiss, H., Godement, P., and Prochiantz, A. Intraneural delivery of protein kinase C pseudosubstrate leads to growth cone collapse. J. Neurosci., 15: 7158-7167, 1995.
18. Fahraeus, R., Paramio, J. M., Ball, K. L., Lain, S., and Lane, D. P. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol., 6: 84-91, 1996.
19. De Gioia, L., Selvaggini. C., Ghibaudi, E., Diomede, L., Bugiani, O., Forloni, G., Tagliavini, F., and Salmona, M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem., 269: 7859-7862, 1994.
20. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
21. Krishan, A., and Frei, E. J. Effect of Adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res., 36: 143-150, 1976.
22. Derossi, D., Joliot, A. H., Chassaing, G., and Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 269: 10444-10450, 1994.
23. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
24. Vikhanskaya, F., Erba, E., D'Incalci, M., and Broggini, M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res., 22: 1012-1017, 1994.